Crude Oil Gains 2%; Macy's Lowers Earnings Forecast

Benzinga
29 May

U.S. stocks traded lower midway through trading, with the Dow Jones index falling around 100 points on Wednesday.

The Dow traded down 0.25% to 42,237.69 while the NASDAQ fell 0.07% to 19,186.35. The S&P 500 also fell, dropping, 0.18% to 5,911.13.

Check This Out: Wall Street’s Most Accurate Analysts Give Their Take On 3 Materials Stocks Delivering High-Dividend Yields

Leading and Lagging SectorsCommunication services shares jumped by 0.5% on Wednesday.

In trading on Wednesday, materials stocks fell by 0.5%.

Top Headline

Macy's Inc. (NYSE:M) on Wednesday revised its annual outlook on initial and current tariffs, some moderation in consumer discretionary spending, and a heightened competitive promotional landscape.

Macy's lowered fiscal 2025 adjusted earnings per share from $2.05-$2.25 to $1.60-$2.00 compared to the consensus of $1.93. Still, the retail giant affirmed its 2025 sales guidance of $21 billion-$21.4 billion versus the consensus of $21.31 billion.

The retailer reported net sales of $4.6 billion for the first quarter of 2025, down 5.1% year over year, beating the consensus of $4.50 billion.

Equities Trading UP           

  • Signing Day Sports, Inc. (NYSE:SGN) shares shot up 270% to $3.0705 after announcing a business combination agreement with BlockchAIn to acquire 100% of the company and form a crypto mining, AI, and high-performance computing data hosting company.
  • Shares of Spero Therapeutics, Inc. (NASDAQ:SPRO) got a boost, surging 205% to $2.0834 after the company and GSK announced the Phase 3 study of tebipenem HBr met its primary endpoint and will stop early for efficacy.
  • Monro, Inc. (NASDAQ:MNRO) shares were also up, gaining 35% to $17.23 after the company reported a fourth-quarter revenue beat and approved a first-quarter cash dividend of $0.28 per share. Additionally, the company announced it has conducted a store portfolio review and has identified 145 underperforming locations for closure.

Equities Trading DOWN

  • InflaRx N.V. (NASDAQ:IFRX) shares dropped 59% to $0.7382 after the company halted Vilobelimab Phase 3 trial in pyoderma Gangrenosum after futility finding in interim analysis.
  • Shares of Cemtrex, Inc. (NASDAQ:CETX) were down 47% to $0.8901 after the company announced a $1.25 million public offering.
  • Tempus AI, Inc. (NASDAQ:TEM) was down, falling 16% to $55.28 after Spruce Point issued a ‘Strong Sell’ opinion on the stock.

CommoditiesIn commodity news, oil traded up 2.1% to $62.14 while gold traded up 0.1% at $3,303.10.

Silver traded down 0.1% to $33.275 on Wednesday, while copper fell 1.1% to $4.6880.

Euro zone

European shares were lower today. The eurozone's STOXX 600 fell 0.38%, while Spain's IBEX 35 Index fell 0.87%. London's FTSE 100 fell 0.28%, Germany's DAX 40 fell 0.43% and France's CAC 40 slipped 0.15% during the session.

Asia Pacific Markets

Asian markets closed lower on Wednesday, with Japan's Nikkei falling 0.005%, Hong Kong's Hang Seng Index dipping 0.53%, China's Shanghai Composite Index falling 0.02% and India's BSE Sensex falling 0.29%.

Economics

  • The volume of mortgage applications in the US declined by 1.2% from the previous week during the week ending May 23.
  • The composite manufacturing index in the US Fifth District rose to -9 in May compared to -13 in April.

Now Read This:

  • Jim Cramer Says This Quantum Computing Stock Is ‘So High’ And ‘Too Speculative’

Photo via Shutterstock

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10